Suvorexant

🧮 Dose calculator

Insomnia · Regimen source: FDA Belsomra · 2.1

• • No more than once per night with at least 7 h before waking. Moderate CYP3A inhibitors → 5 mg; strong inhibitors not recommended. FDA Belsomra · 2.1FDA Belsomra · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Belsomra · 8.1

  “Risk Summary Available data from postmarketing reports with BELSOMRA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Belsomra · 8.2

  “Risk Summary Suvorexant and its metabolite, hydroxy suvorexant, are present in low concentrations in breast milk with a relative infant dose of less than 1% following maternal oral administration (see Data ) .”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Belsomra · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Belsomra · 8.5

  “Because BELSOMRA can increase drowsiness, patients, particularly the elderly, are at a higher risk of falls [see Warnings and Precautions (5.1) ] .”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.